New Applications of Oleanolic Acid and its Derivatives as Cardioprotective Agents: A Review of their Therapeutic Perspectives

2019 ◽  
Vol 25 (35) ◽  
pp. 3740-3750 ◽  
Author(s):  
Ning Sun ◽  
Dongli Li ◽  
Xiaoqing Chen ◽  
Panpan Wu ◽  
Yu-Jing Lu ◽  
...  
Keyword(s):  
Oleanolic Acid ◽  
Liver Diseases ◽  
Therapeutic Agent ◽  
Heart Diseases ◽  
Pentacyclic Triterpenoids ◽  
Hepatic Drug ◽  
Approved Drugs ◽  
New Applications ◽  
Functional Mechanisms ◽  
Potent Therapeutic Agent

Oleanolic acid is an analogue of pentacyclic triterpenoids. It has been used as a hepatic drug for over 20 years in China. Currently, there are only five approved drugs derived from pentacyclic triterpenoids, including oleanolic acid (liver diseases), asiaticoside (wound healing), glycyrrhizinate (liver diseases), isoglycyrrhizinate (liver disease) and sodium aescinate (hydrocephalus). To understand more about the bioactivity and functional mechanisms of oleanolic acid, it can be developed as a potent therapeutic agent, in particular, for the prevention and treatment of heart diseases that are the leading cause of death for people worldwide. The primary aim of this mini-review is to summarize the new applications of oleanolic acid and its derivatives as cardioprotective agents reported in recent years and to highlight their therapeutic perspectives in cardiovascular diseases.

scholarly journals Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma

2017 ◽  
Vol 8 (9) ◽  
pp. e3050-e3050 ◽  
Author(s):  
Xinhua Xiao ◽  
Huiliang Li ◽  
Huizi Jin ◽  
Jin Jin ◽  
Miao Yu ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Therapeutic Agent ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Potent Therapeutic Agent

Psychological prognosis after newly diagnosed chronic conditions: socio-demographic and clinical correlates

2016 ◽  
Vol 29 (2) ◽  
pp. 281-292 ◽  
Author(s):  
Ching-Ju Chiu ◽  
Yu-Ching Hsu ◽  
Shuo-Ping Tseng
Keyword(s):  
Depressive Symptoms ◽  
Depressive Symptom ◽  
Chronic Conditions ◽  
Liver Diseases ◽  
Lung Diseases ◽  
Heart Diseases ◽  
Psychological Burden ◽  
Symptom Trajectories ◽  
Physical Limitations ◽  
Over Time

ABSTRACTBackground:This study was aimed toward discerning depressive symptom trajectories associated with different chronic conditions and toward finding modifiable factors associated with those trajectories.Methods:Data were drawn from the 1996–2007 Taiwan Longitudinal Study on Aging. Nine chronic conditions were selected, and mood trajectories were measured with the Center of Epidemiological Studies-Depression scale.Results:Among the nine chronic conditions we examined, four patterns of depressive symptom trajectories were identified: (1) elevated depressive symptoms and worsened over time after diagnosed with heart disease (n= 681), arthritis (n= 850), or hypertension (n= 1,207); (2) elevated depressive symptoms without worsening over time after diagnosed with stroke (n= 160), lung diseases (n= 432), gastric conditions (n= 691), or liver diseases (n= 234); (3) no elevated depressive symptoms after diagnosis but an increase in depressive symptoms over time for participants with diabetes (n= 499); and (4) no significant patterns after diagnosed with cancer (n= 57). Cumulative psychological burden over time was significant for participants with hypertension, diabetes, heart diseases, or arthritis. However, these effects disappeared after controlling for comorbidities and physical limitations. Moreover, psychiatric condition was found to play an important role in baseline depressive symptoms among participants diagnosed with lung diseases, arthritis, or liver diseases.Conclusions:Findings from this study provide information in addressing psychological burden at different times for different conditions. In addition, minimizing the incidence of comorbidities, physical limitations, or psychiatric conditions may have the prospective effect of avoiding the trend of increased depressive symptoms, especially when adults diagnosed with hypertension, diabetes, heart diseases, arthritis, lung diseases, arthritis, or liver diseases.

The life cycle and in silico elucidation of non-structural replicating proteins of HCV through a pharmacoinformatics approach

2021 ◽  
Vol 24 ◽  
Author(s):  
Rana Adnan Tahir ◽  
Sumera Mughal ◽  
Amina Nazir ◽  
Asma Noureen ◽  
Ayesha Jawad ◽  
...  
Keyword(s):  
Life Cycle ◽  
In Silico ◽  
Liver Diseases ◽  
Rna Virus ◽  
The Novel ◽  
Nonstructural Proteins ◽  
Drug Molecules ◽  
Liver Transplantations ◽  
Pharmacophore Generation ◽  
Approved Drugs

Background: Hepatitis C virus (HCV) is an enveloped and positive-stranded RNA virus that is a major causative agent of chronic liver diseases worldwide. HCV has become the main cause of liver transplantations and there is no effective drug for all hepatitis genotypes. Elucidation of life cycle and nonstructural proteins of HCV involved in viral replication are the attractive targets for the development of antiviral drugs. Methods: In this work, pharmacoinformatics approaches coupled with docking analyses were applied on HCV nonstructural proteins to identify the novel potential hits and HCV drugs. Molecular docking analyses were carried out on HCV approved drugs followed by the ligand-based pharmacophore generation to screen the antiviral libraries for novel potential hits. Results: Virtual screening technique has made known the top-ranked five novel compounds (ZINC00607900, ZINC03635748, ZINC03875543, ZINC04097464, and ZINC12503102) along with the least binding energy (-8.0 kcal/mol, -6.1 kcal/mol, -7.5 kcal/mol, -7.4 kcal/mol, and -7.3 kcal/mol respectively) and stability with non-structural proteins target. Conclusion: These promising hits exhibited better absorption and ADMET properties as compared to the selected drug molecules. These potential compounds extracted from in silico approach may be significant in drug design and development against Hepatitis and other liver diseases.

scholarly journals Scabiosa Genus: A Rich Source of Bioactive Metabolites

Medicines ◽  
2018 ◽  
Vol 5 (4) ◽  
pp. 110 ◽  
Author(s):  
Diana Pinto ◽  
Naima Rahmouni ◽  
Noureddine Beghidja ◽  
Artur Silva
Keyword(s):  
Secondary Metabolites ◽  
Liver Diseases ◽  
Mediterranean Region ◽  
Folk Medicine ◽  
In Vivo Studies ◽  
Bioactive Metabolites ◽  
Pentacyclic Triterpenoids ◽  
Medical Settings ◽  
Plant Names

The genus Scabiosa (family Caprifoliaceae) is considered large (618 scientific plant names of species) although only 62 have accepted Latin binominal names. The majority of the Scabiosa species are widely distributed in the Mediterranean region and some Scabiosa species are used in traditional medicine systems. For instance, Scabiosa columbaria L. is used traditionally against diphtheria while S. comosa Fisch. Ex Roem. and Schult. is used in Mongolian and Tibetan traditional medical settings to treat liver diseases. The richness of Scabiosa species in secondary metabolites such as iridoids, flavonoids and pentacyclic triterpenoids may contribute to its use in folk medicine. Details on the most recent and relevant pharmacological in vivo studies on the bioactive secondary metabolites isolated from Scabiosa species will be summarized and thoroughly discussed.

Abstract P3-14-23: Affitoxin — A Potent Therapeutic Agent for Treatment of HER2- Overexpressing Tumors

2010 ◽  
Author(s):  
R Zielinski ◽  
I Lyakhov ◽  
M Hassan ◽  
M Kuban ◽  
K Shafer-Weaver ◽  
...  
Keyword(s):  
Therapeutic Agent ◽  
Potent Therapeutic Agent

scholarly journals Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

2016 ◽  
Vol 76 (10) ◽  
pp. 3003-3013 ◽  
Author(s):  
Pia M. Challita-Eid ◽  
Daulet Satpayev ◽  
Peng Yang ◽  
Zili An ◽  
Karen Morrison ◽  
...  
Keyword(s):  
Therapeutic Agent ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Cancer Models ◽  
Potent Therapeutic Agent ◽  
Antibody Drug

A Pharmaceutico-Analytical Study of Bhunaga Satva

2018 ◽  
Vol 3 (3) ◽  
Author(s):  
Manish Kumar Patel ◽  
Archana . ◽  
Lalchand . ◽  
Saroj Parhate
Keyword(s):  
Quantitative Analysis ◽  
Medical Practice ◽  
Manufacturing Process ◽  
Analytical Study ◽  
Therapeutic Agent ◽  
Qualitative And Quantitative Analysis ◽  
Qualitative And Quantitative ◽  
Percentage Yield ◽  
Potent Therapeutic Agent

The knowledge of Tamra (copper) was known to Indians, since early ages of medical practice. It is having the Rasayana, emetic, purgative, blood purifying properties. Ashodhita Copper causes Vanti (vomiting) and Bhranti (mental illusion). So it should be used after Shodhana only. Various pharmaceutical procedures i.e. Shodhana (purification), Marana (incineration), Satvapatana (extraction of metal from mineral) etc. converts deadly toxic mineral, metallic substances into safe and potent therapeutic agent. Bhunaga (earthworm) Satva has been mentioned as a source of Tamra (copper). This paper aims to make available standard manufacturing process of Bhunaga Satva-Patana. Satvapatana process performed by method described in Rasa Tarangini. 2 gm of Satva was obtained from 120 gm of Bhunaga Masi. Percentage yield of Satva was 1%. The prepared Satva’s were subjected to qualitative and quantitative analysis. In Bhunaga there was Satva higher percent of Fe (75.3%) along with containing Cu 18.8% and Zn 2%.

scholarly journals Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks

2015 ◽  
Vol 59 (10) ◽  
pp. 5892-5902 ◽  
Author(s):  
Azizul Haque ◽  
Didier Hober ◽  
Joel Blondiaux
Keyword(s):  
Virus Infection ◽  
Ebola Virus ◽  
Therapeutic Agent ◽  
Cell Types ◽  
Rapid Evaluation ◽  
Hemorrhagic Disease ◽  
Treatment And Prevention ◽  
Approved Drugs ◽  
Ebola Virus Infection

ABSTRACTEbola virus can cause severe hemorrhagic disease with high fatality rates. Currently, no specific therapeutic agent or vaccine has been approved for treatment and prevention of Ebola virus infection of humans. Although the number of Ebola cases has fallen in the last few weeks, multiple outbreaks of Ebola virus infection and the likelihood of future exposure highlight the need for development and rapid evaluation of pre- and postexposure treatments. Here, we briefly review the existing and future options for anti-Ebola therapy, based on the data coming from rare clinical reports, studies on animals, and results fromin vitromodels. We also project the mechanistic hypotheses of several potential drugs against Ebola virus, including small-molecule-based drugs, which are under development and being tested in animal models orin vitrousing various cell types. Our paper discusses strategies toward identifying and testing anti-Ebola virus properties of known and medically approved drugs, especially those that can limit the pathological inflammatory response in Ebola patients and thereby provide protection from mortality. We underline the importance of developing combinational therapy for better treatment outcomes for Ebola patients.

Sign in / Sign up

Export Citation Format

Share Document